---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000043"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:21:16.337445+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review

## Summary
- Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.
- Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.
- 4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.
- PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.
- Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1.

## SEC filing metadata
- accession: 0001645113-25-000043
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/0001645113-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/nvcr-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000043
- JSON: https://secwatch.observer/filing/0001645113-25-000043.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.